CompletedPHASE2, PHASE3NCT01685827

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

Studying African trypanosomiasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Victor KANDE, MD
HAT National Control Program in DRC
Intervention
Fexinidazole(drug)
Enrollment
394 enrolled
Eligibility
15 years · All sexes
Timeline
20122017

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01685827 on ClinicalTrials.gov

Other trials for African trypanosomiasis

Additional recruiting or active studies for the same condition.

See all trials for African trypanosomiasis

← Back to all trials